

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer ID5094

Provisional Stakeholder List

Consultees	Commentators (no right to submit or appeal)
Company	General
Merck Sharp & Dohme	All Wales Therapeutics and Toxicology
(pembrolizumab)	Centre
	 Allied Health Professionals Federation
Patient/carer groups	 Board of Community Health Councils in
Asthma and Lung UK	Wales
Black Health Agency for Equality	 British National Formulary
Cancer Black Care	 Care Quality Commission
Cancer Equality	 Department of Health, Social Services
Helen Rollason Cancer Charity	and Public Safety for Northern Ireland
Independent Cancer Patients Voice	 Healthcare Improvement Scotland
Macmillan Cancer Support	Medicines and Healthcare products
Maggie's Centres	Regulatory Agency
Marie Curie	National Association of Primary Care
Oncogene-Driven Lung Cancer	National Pharmacy Association
Patient Alliance UK	NHS Confederation
Roy Castle Lung Cancer Foundation	Scottish Medicines Consortium
Ruth Strauss Foundation	Welsh Government
South Asian Health Foundation	Welsh Health Specialised Services
Specialised Healthcare Alliance	Committee
Tenovus Cancer Care	Dossible comparator companies
UK Lung Cancer Coalition	Possible comparator companiesAspire Pharma (pemetrexed)
Hoolthoore professional groups	 Aspire Pharma (perhetrexed) Bristol Myers Squibb (nivolumab,
 Healthcare professional groups Association of Anaesthetists 	paclitaxel)
 Association of Anacstrictists Association of Cancer Physicians 	 Dr Reddy's Laboratories (pemetrexed)
 Association of Cancer i Hysicians Association of Respiratory Nurse 	Eli Lilly (pemetrexed)
Specialists	Genus Pharmaceuticals (pemetrexed)
Association of Surgeons of Great	Medac (oxaliplatin)
Britain and Ireland	Pfizer (cisplatin, carboplatin, docetaxel
British Geriatrics Society	oxaliplatin, paclitaxel, pemetrexed)
British Institute of Radiology	Ranbaxy (oxaliplatin)
British Oncology Pharmacy	Roche (atezolizumab)
Association	 Sandoz (cisplatin, pemetrexed)

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer ID5094 Issue date: November 2023



Consultees	Commentators (no right to submit or appeal)
 British Psychosocial Oncology Society British Society of Interventional Radiology British Thoracic Oncology Group British Thoracic Society British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Seacross Pharmaceuticals (paclitaxel, oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed) Relevant research groups Cochrane Lung Cancer Group Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency


NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Provisional stakeholder list for the evaluation of pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer ID5094 Issue date: November 2023



organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.